Start a conversation ↗Knowledge centre
Selected developments shaping clinical research, bioequivalence and the regulatory environment in Malaysia, ASEAN and beyond.
Latest intelligence
Regional clinical-trial and pharmaceutical developments
Malaysia’s Evolving Rare Disease Ecosystem and the Future of Orphan Drug Access - BioSpectrum AsiaThe Biomedical Industry: Accelerated Upgrade Path (1) - HKTDC ResearchRunning first-in-human clinical trials for drugs in Malaysia - The StarA systematic review and meta-analysis of pharmacy education and practice on prevention and management of noncommunicable diseases in ASEAN countries - NatureMethods, products and development strategy
Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions - NaturePharmacokinetic and bioequivalence of two formulations of Valsartan/Amlodipine Tablet(I) in healthy Chinese volunteers: A randomized, three-period, partially replicated crossover study - NatureSix business lessons from Cipla’s nine-decade journey - Express PharmaComplex Generics: Facts, Figures and Who They Benefit - Teva PharmaceuticalsGuidance and announcements from medicines regulators
Asia-Pacific Roundup: TGA adopts 23 international scientific guidelines - RAPSQPS India Successfully Completes Week-Long US FDA Regulatory Inspection - Business WireTechnology influencing trial design and delivery
AI in Clinical Trials Doesn’t Have a Capability Problem. It Has a Honesty Problem. - The Clinical Trial VanguardNature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks - Kosmo OnlineShaalan Beg: When AI Enters the Clinic - OncodailyAI in clinical trials: Building better trials before they start - pharmaphorum